| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Regenerative Biotech | 0 | 0 | NaN | NaN |
| Consumer Health Products | 226 | 704 | NaN | NaN |
| Product revenue | 226 | 704 | NaN | NaN |
| Regenerative Biotech | 0 | 0 | NaN | NaN |
| Consumer Health Products | 206 | 646 | NaN | NaN |
| Cost of sales | 206 | 646 | NaN | NaN |
| Regenerative Biotech | 563 | 2,653 | NaN | NaN |
| Consumer Health Products | 0 | 0 | NaN | NaN |
| Research and development | 563 | 2,653 | NaN | NaN |
| Sales and marketing | 18 | 67 | NaN | NaN |
| General and administrative | 1,045 | 4,253 | NaN | NaN |
| Total operating expenses | 1,832 | 7,619 | NaN | NaN |
| Regenerative Biotech | -5 | NaN | NaN | NaN |
| Consumer Health Products | 0 | NaN | NaN | NaN |
| Other segment items | -5 | -46 | NaN | NaN |
| Net loss | -1,601 | -1,687 | -1,700 | -3,482 |
| Share-based compensation expense | 632 | 493 | 495 | 1,022 |
| Depreciation | 1 | 1 | 1 | 3 |
| Amortization of operating lease right-of-use assets | 27 | 26 | 24 | 48 |
| Accounts receivable | 0 | 13 | -2 | -226 |
| Inventory | -1 | -6 | -5 | -53 |
| Prepaid research and development | NaN | -35 | 0 | -37 |
| Prepaid expenses and other current assets | -22 | -32 | -16 | -101 |
| Deferred financing costs | NaN | 0 | 0 | 0 |
| Long-term prepaid contracts | 105 | -44 | -76 | -137 |
| Accounts payable | -215 | 141 | -39 | -100 |
| Operating lease liability | -26 | -25 | -25 | -45 |
| Accrued and other current liabilities | 307 | 205 | -236 | 342 |
| Deferred revenue | 88 | 124 | -21 | 149 |
| Insurance premium financing payable | -68 | -46 | -63 | -190 |
| Net cash used in operating activities | -937 | -664 | -1,465 | -1,699 |
| Proceeds from convertible debt related party | NaN | 0 | 0 | 0 |
| Proceeds from issuance of common stock | NaN | 700 | 2,000 | 0 |
| Proceeds from exercise of warrants | NaN | 0 | 0 | NaN |
| Payments on convertible debt related party | NaN | 0 | 0 | NaN |
| Net cash provided by financing activities | NaN | 700 | 2,000 | 0 |
| Effect of exchange rate changes on cash | 4 | -3 | -2 | -1 |
| Net decrease in cash and cash equivalents | -933 | 33 | 533 | -1,700 |
| Cash and cash equivalents at the beginning of the year | 1,352 | 1,319 | 2,486 | NaN |
| Cash and cash equivalents at the end of the period | 419 | 1,352 | 1,319 | NaN |
Harvard Apparatus Regenerative Technology, Inc. (HRGN)
Harvard Apparatus Regenerative Technology, Inc. (HRGN)